Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
International Journal of Hematology
|
September 29, 2022
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
Noriko Fukuhara, Dai Maruyama, Kiyohiko Hatake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2017
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M Dreyling, F Morschhauser, K Bouabdallah, et al.
Genome Medicine
|
March 1, 2022
DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors
Tincy Simon, Pamela Riemer, Armin Jarosch, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Blood
|
February 3, 1998
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease
E B Papadopoulos, M H Carabasi, H Castro-Malaspina, et al.
Journal of Neuro-Oncology
|
December 23, 2003
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
Lauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
Neuro-Oncology
|
March 10, 2006
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
Lauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
American Journal of Hematology
|
December 24, 2019
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Targeted Oncology
|
December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Jean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
The Journal of Clinical Ethics
|
December 22, 2012
HCEC pearls and pitfalls: suggested do's and don't's for healthcare ethics consultants
, Joseph A Carrese, Armand H Matheny Antommaria, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
International Journal of Hematology
|
September 29, 2022
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
Noriko Fukuhara, Dai Maruyama, Kiyohiko Hatake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2017
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M Dreyling, F Morschhauser, K Bouabdallah, et al.
Genome Medicine
|
March 1, 2022
DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors
Tincy Simon, Pamela Riemer, Armin Jarosch, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Blood
|
February 3, 1998
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease
E B Papadopoulos, M H Carabasi, H Castro-Malaspina, et al.
Journal of Neuro-Oncology
|
December 23, 2003
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
Lauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
Neuro-Oncology
|
March 10, 2006
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
Lauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
American Journal of Hematology
|
December 24, 2019
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Targeted Oncology
|
December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Jean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
The Journal of Clinical Ethics
|
December 22, 2012
HCEC pearls and pitfalls: suggested do's and don't's for healthcare ethics consultants
, Joseph A Carrese, Armand H Matheny Antommaria, et al.
Page
of 9